Sage’s Depression Results Put Eyes on Marinus

Shares of Sage Therapeutics (SAGE) climbed higher on Tuesday with the first glimpse at SAGE-547’s potential in post-partum depression. And with it went Marinus Pharmaceuticals (MRNS), the lightly-followed developer of a similar neurosteroid candidate, ganaxolone.

Read more about both drug candidates in our previous coverage.